Invention Grant
- Patent Title: ZAQ ligand-1 antibodies and uses thereof
- Patent Title (中): ZAQ配体-1抗体及其用途
-
Application No.: US10542664Application Date: 2004-01-21
-
Publication No.: US07662380B2Publication Date: 2010-02-16
- Inventor: Hirokazu Matsumoto , Yasuko Horikoshi , Yasushi Masuda , Tetsuya Ohtaki
- Applicant: Hirokazu Matsumoto , Yasuko Horikoshi , Yasushi Masuda , Tetsuya Ohtaki
- Applicant Address: JP Osaka
- Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee: Takeda Pharmaceutical Company Limited
- Current Assignee Address: JP Osaka
- Agency: Foley & Lardner LLP
- Priority: JP2003-014055 20030122
- International Application: PCT/JP2004/000498 WO 20040121
- International Announcement: WO2004/065419 WO 20040805
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C12N5/12

Abstract:
The antibody of the present invention has an extremely high binding ability to human ZAQL-1, can neutralize the activity of human ZAQL-1, and inhibits the action of human ZAQL-1. Therefore, the antibody is useful as a preventive or therapeutic agent or a diagnostic agent for, e.g., digestive diseases, diseases associated with angiogenesis, diseases relating to pregnancy, eating disorders, sleeping disorders, seasonal depression, reproductive dysfunction, endocrine diseases, senile dementia, Alzheimer's disease, various disorders caused by aging, cerebral circulatory disorders, head trauma, spinal injury, epilepsy, anxiety, depression, manic depression, schizophrenia, alcoholism, Parkinson's disease, hypertension, arteriosclerosis, arrhythmia, premenstral syndrome, glaucoma, cancer, AIDS, diabetes, etc.
Public/Granted literature
- US20060217536A1 Antibody and use thereof Public/Granted day:2006-09-28
Information query